<DOC>
	<DOCNO>NCT02022306</DOCNO>
	<brief_summary>This study consist two part , Parts A B . Part A single ascending dose ( SAD ) study healthy subject . Part B multiple ascend dose ( MAD ) study healthy subject .</brief_summary>
	<brief_title>TD-6450 SAD MAD Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Subject female nonchildbearing potential male , healthy , nonsmoking , 18 60 year old , inclusive , screen . Females consider non childbearing potential hysterectomy tubal ligation ( documentation require ) postmenopausal ( amenorrheic least 2 year ) follicle stimulate hormone ( FSH ) level &gt; 40 IU/L Subject body mass index 18 30 kg/m2 , inclusive , weigh least 50 kg . Subject evidence history clinically significant allergic ( except untreated , asymptomatic , seasonal allergy time dose ) , hematological , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurological disease . Subject estimate creatinine clearance &lt; 90 mL/min Screening Day 1 , calculate use CockcroftGault equation . Subject participate another clinical trial investigational drug ( medical device ) within 60 day prior Screening , currently participate another trial investigational drug ( medical device ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Hepatitis C</keyword>
</DOC>